+34 620 10 75 37info@nanbiosis.com

Nanbiosis

U1. Protein Production Platform Unit (PPP)

U1. Protein Production Platform (PPP)

U1. PPP logo IBB UAB

Order request

Description

The PPP Unit is at the Institute of Biotechnology and Biomedicine of the Autonomous University of Barcelona (IBB-UAB). It counts with the necessary facilities for the design, production, and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, led by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer a “tailored” service for the design, production, and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic, X-ray crystallography, and Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.

Counts with a laboratory perfectly equipped for the bioproduction of proteins, another with all the necessary equipment for molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.

The PPP Unit has implemented the ISO9001 certification for standard quality control system.

IQNet ISO 9001:2015 Certification PPP

AENOR ISO 9001:2015 Certification PPP

Active projects

Title Fundin: Organism Call: Funding source Role
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
PI15/00272 Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer. Instituto de Salud Carlos III Participant
BIO2013-41019-P ENGINEERING OF PROTEIN NANOPARTICLES FOR THE DIRECT DELIVERY OF THERAPEUTIC PROTEINS AND NUCLEIC ACIDS MINECO Participant
2014SGR-132 Basic and Applied Microbiology AGAUR Participant
BIO2016-76063-R DEVELOPMENT OF NONOSTRUCTURED PROTEIN TOXINS AND POISONS FOR THE TREATMENT OF CXCR4 + CANCERES MINECO Working package
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant
Marato 416/C/2030TV32013-132031 Genotoxic nanoparticles targeting colorectal cancer stem cells Marato TV3 Participant

Publications


2016

  • Corchero J.L. Eukaryotic aggresomes: from a model of conformational diseases to an emerging type of immobilized biocatalyzers. Applied Microbiology and Biotechnology. 2016;100(2):559-569.
  • Saccardo P., Corchero J.L., Ferrer-Miralles N.. Tools to cope with difficult-to-express proteins. Applied Microbiology and Biotechnology. 2016;:1-9.
  • Torrealba D., Seras-Franzoso J., Mamat U., Wilke K., Villaverde A., Roher N. et al. Complex particulate biomaterials as immunostimulant-delivery platforms. PLoS ONE. 2016;11(10)
  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.
  • Serna N., Cespedes M.V., Saccardo P., Xu Z., Unzueta U., Alamo P. et al. Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(5):1241-1251.
  • Rueda F., Gasser B., Sanchez-Chardi A., Roldan M., Villegas S., Puxbaum V. et al. Functional inclusion bodies are produced in the yeast Pichia pastoris. Microbial Cell Factories. 2016;15(1)
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models.Nanomedicine : nanotechnology, biology, and medicine. 2016;12(7)
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U1

27 Dec

NANBIOSIS U1_Protein Production Platform expands its facilities at the Autonomous University of Barcelona, strengthening its capabilities.

NANBIOSIS Unit 1 Protein Production Platform (PPP) of CIBER-BBN and UAB, has taken a significant step towards enhancing its service capabilities in the field of recombinant protein production and purification. Until now, due to space constraints at the Institute of Biotechnology and Biomedicine (IBB), U1’s activities were confined to half of a small laboratory. However, thanks to the ongoing commitment of the center to bolster the PPP’s activities, this unit has gained access to a laboratory, along with an office, exclusively designated for the platform within the IBB premises, creating an optimal environment for the process of protein production and[...]

20 Dec

Good News! Protein Nanoparticles with a New Ligand Select and Destroy Tumor-associated Fibroblasts”

With the participation of two units of NANBIOSIS ICTS and the expertise of the scientists managing these units The study, fruit of the collaboration between the Nanotechnology group of the Institute of Biotechnology and Biomedicine (IBB-UAB), led by Prof. Antonio Villaverde, and the Oncogenesis and Antitumor Drugs group of the Sant Pau Research Institute, led by Dr. Ramon Mangues, both members of CIBER-BBN, has made significant progress by identifying the natural ligand PDGFD as an effective tool to target protein nanoparticles to tumor-associated fibroblasts that overexpress the PDGFR-β receptor. Given the relevance of the discovery, this technology has been intellectually[...]

30 Nov

NANBIOSIS U1 PPP invited to PEGS, the Protein & Antibody Engineering Summit

*Image explained by Merce Márquez Martínez, Coordinator of NANBIOSIS U1 The NBT group and Unit 1 of NANBIOSIS (Protein Production Platform, PPP), from CIBER-BBN and IBB-UAB, participated in the 15th PEGS Europe conference held in Lisbon from November 14th to 16th. PEGS, or the Protein & Antibody Engineering Summit, is a prestigious conference, organized by the Cambridge Healthtech Institute (CHI), focusing on protein engineering and its applications in drug discovery, development, and delivery. This conference serves as a valuable platform for knowledge exchange among researchers, scientists, industry experts, and professionals in the field of protein science. From left to right,[...]

08 Nov

Impactful research with NANBIOSIS participation in the Poster Tour of CIBER-BBN & CIBEREHD Annual Conference.

2023 CIBER-BBN Annual meeting has taken place at Santemar Hotel, in Santander during November 6-7. This year the format of our annual conferences has been changed towards a collective event scheme between the CIBER-BBN and CIBEREHD thematic areas. On Monday 6 the scientific sessions werecommon for EHD and BBN, with appealing contents for the mixed audience. On Tuesday 7 EHD and BBN sessions will specific for each area in separate rooms (with common coffee break). Posters of both areas were on display in the exhibit hall throughout the entirety of the Annual Meeting. Moreover, at the “Posters & beers” session (Monday[...]

23 Oct

NANBIOSIS U1 at UAB Innovation Fair

On October 17, 2023, the NANBIOSIS U1 of Protein Production Platform PPP, took part in the UAB Innovation Fair, where various research groups, spin-offs, service providers, research centers, and companies gathered to foster networking opportunities. This event proved highly advantageous for the PPP, as it not only facilitated the identification of potential new clients but also paved the way for collaborative efforts aimed at enhancing and refining the final product offered by the PPP. PPP NANBIOSIS U1 Scientists at PPP stand at the Fair: Neus Ferrer, Scientific Director; Rosa Mendoza, Laboratory Manager, and Mercedes Marquez, Scientific Coordinator. The UAB Innovation[...]

28 Sep

Nanoligent raised €2.8 M and completed Seed round financing with support of i&i Biotech Fund

September 27th 2022 – Nanoligent SL, a Spanish biotech company specialized in the development of cancer treatments based on unique protein conjugates, today announces the completion of a Seed financing round of total € 2.8 M. The final closing of the Seed round consists of € 1 M investment by i&i Biotech Fund I (i&i Bio), an early-stage Life Science fund with teams in Luxemburg and Prague which is backed by the European Investment Fund. i&i Bio joined previous Nanoligent investors, Italian Angels for Growth, the largest network of business angels in Italy, and AVANTECA Partners, a Swiss privately held[...]

16 Aug

Two NANBIOSIS Units of CIBER-BBN at UAB, one of the 300 best universities in the world, according the Shanghai Ranking

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the Autonomous University of Barcelona among the elite of the 300 best universities in the world. This indicator organizes up to 20,000 university centers worldwide,based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings Two of NANBIOSIS Units created by UAB and CIBER-BBN are part of this university: U1 Protein Production Platform (PPP), led by Toni Villaverde, Neus Ferrer and Mercedes Marquez, offer an “tailored” service for the design,[...]

25 Jun

How engineered protein helps Nanomedicine againts Cancer

The use of protein nanoparticles as biomaterials have been rising in recent years due to their characteristics: high biocompatibility, structural versatility, biodegradability and plasticity of design. We can later incorporate peptide ligands for specific targeting as fusion proteins and use these nanoparticles for targeted nanomedicine. However, not all proteins can be used as scaffolds for targeted drug delivery, as they need to meet certain criteria. First, it is crucial that the proteins used as a scaffold allow site-specific drug conjugation. The stability and proteolysis resistance of these proteins is also important to remain assembled during the bloodstream circulation. In addition,[...]

U1-Protein Production Platform - PPP
Read More

U2. Custom Antibody Service Unit (CAbS)

U2 CAbS-hybridoma clone

U2. Custom Antibody Service (CAbS)

  • Scientific Director: Prof. Pilar Marco pilar.marco@cid.csic.es
  • Scientific Coordinator: Dra. Nuria Pascual npdqob@cid.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC

IQAC CSIC

Order request

Description

The facility is located in the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC; Barcelona). It is equipped with a laboratory for the development and production of monoclonal antibodies. The laboratory is fully equipped for obtaining, selecting and storing monoclonal antibody producing hybridomas. In addition, the facility has infrastructure for the production of polyclonal antibodies, as well as laboratories for the synthesis of bioconjugates, haptens, the purification of antibodies and the performance of immunoassays. In addition to the above mentioned equipment, the IQAC-CSIC provides animal husbandry facilities and a unit for the synthesis of organic molecules.

The equipment consists in an inverted phase contrast microscope with a camera, two Class II laminar flow biological safety cabinets, two CO2 incubators, a bioreactor for hybridoma culture, and tangential filtration unit for purification of the antibodies produced in the culture. Among the items of available equipment it should be highlighted a spotter for selection of high antibody producing cell lines and an automated ELISA microplate washer an ELISA reader, two AKTA Prime Liquid chromatography systems for antibody purification, plus standard equipment (centrifuges, fridges, liquid nitrogen containers, autoclave, baths, and vacuum equipment) and all the necessary routine laboratory apparatus.Cabs also has access to a fully equipped chemistry laboratory for the synthesis of haptens and immunoreagents.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
PIE1400061 Molecular links between diabetes and neurodegenerative diseases ISCIII Oberver
2014SGR1484 Consolidated Research Group Generalitat de Catalunya Participant
FP7-614168 Real time monitoring of SEA contaminants by an autonomous Lab-on-a-Chip biosensor (SEA-on-a-CHIP) European Commission Oberver
CI16-00031 Caixa Impulse A new approach for the detection of Pseudomonas aeruginosa CaixaBank Participant
MSCA-ITN2015-675412 New Diagnostics for Infectious Diseases European Commission Participant
TECCTP15-1-0011 Ajuda acreditació Tecnio del grup Nb4D ACCIÓ: Generalitat de Catalunya Others

Publications


2016

  • Roncador G., Engel P., Maestre L., Anderson A.P., Cordell J.L., Cragg M.S. et al. The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs. 2016;8(1):27-36.
  • Pastells C., Pascual N., Sanchez-Baeza F., Marco M.-P.. Immunochemical Determination of Pyocyanin and 1-Hydroxyphenazine as Potential Biomarkers of Pseudomonas aeruginosa Infections. Analytical Chemistry. 2016;88(3):1631-1638.
  • Salvador J.-P., Marco M.-P.. Amperometric Biosensor for Continuous Monitoring Irgarol 1051 in Sea Water. Electroanalysis. 2016;28(8):1833-1838.

News U2

24 Nov

From the molecule to the bioassay by Custom antibody service (CAbS)-NANBIOSIS U2 as a PTI+Global Health Infraestructure

During 20-22 of November 2023, the III PTI+Global Health Scientific Conference were held in the Center for Human and Social Sciences, in Madrid. In March 2020, the CSIC (Spanish National Research Council) launched the the Interdisciplinary Thematic Platform (PTI) on Global Health to bring together research teams and enhance knowledge about the new coronavirus SARS-CoV-2, which caused the pandemic. The PTI has mobilized and coordinates more than 400 scientists from 50 CSIC institutes in all areas. The annual PTI+Global Health Scientific Conference are a meeting space where the results of the research carried out in the laboratories can be shown[...]

08 Nov

NANBIOSIS sesion in the CIBER-BBN and CIBEREHD annual meeting. SAFE-N-MEDTECH Project: Outcomes and Future Prospects.

The annual conference of the scientific áreas of CIBER (the most important Centre for Biomedical Research in Spain) are hotly awaited every year for the CIBER community as a foro to be updated about emerging key technologies and discuss about research lines and results, find new opportunities to collaborate and join efforts towards common objectives. Moreover, this year, the Annual Conference of CIBER-BBN (Bioengineering, Biomaterials and Nanomedicine) has been organized as a collective event scheme together with the scientific area of CIBEREHD (Digestive and Liver Diseases). Both areas have already shared experiences of collaborative projects, demonstrating the complementarity of their fields.[...]

20 Oct

The importance of bacterial Quorum Sensing (QS) research recognised in the Princesa of Asturias Awards

Today, Bonnie Bassler, Jeffrey Gordon, and Peter Greenberg are receiving the Princess of Asturias Award for their contribution to the knowledge of the role of the human microbiome and the bacteria Quorum Sensing. Targeting Quorum Sensing allows understanding of bacteria behaviour and pathogenesis, but also developing new therapeutic and diagnostic strategies for infectious diseases. Bonnie Bassler has shown how small chemical signals are involved in such a communication process. Peter Greenberg was one of the first scientists who assigned the term Quorum Sensing (QS) to such a sophisticated system used by bacteria to communicate and synchronize behavior. He was involved[...]

15 May

New look of Nb4D – CAbS (NANBIOSIS U2) “Revolutionising Diagnosis”

Nb4D has a new look on line! Nb4D Group (of IQAC-CSIC and CIBER-BBN) has lunched a new website “Revolutionsising Diagnosis“ with the aim to facilitate a faster and easier navigation througth their “pioneering research to develop new diagnostic and therapeutic approaches” and their solutions and expertise to help researchers and companies. Antibodies, bioreceptors, hapten design and synthesis, immunoanalytical method development, new ivd tools, surface functionalization, therapeutic antibodies and much more knowledge and expertise revolutionising diagnosis. The new website contains a page for CAbS-NANBIOSIS. Custom Antibody Service (CAbS), unit 2 of the ICTS NANBIOSIS[...]

28 Feb

Rare diseases international day 2023: some NANBIOSIS contributions

Today is the international day of rare diseases, a day to raise awareness and instigate change for people living with a rare disease. From NANBIOSIS we want to sume to this celebration and higtligh our commitment to helping people with rare diseases through research. Dr. Ibane Abasolo, Scientific Director of NANBIOSIS U20, was at the WORLDSymposia conference last week in Orlando (FL, USA), where the latest advances in preclinical study and clinic of lysosomal storage diseases were explained. There, she presented the results obtained in the Smart4Fabry project coordinated by the CIBER-BBN where nanoliposomes were developed for the treatment of[...]

27 Feb

New method for the detection of RNA viruses such as SARS-CoV-2

Several CIBER-BBN groups at the University of Barcelona, the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC) and the Institute of Nanoscience and Materials of Aragon (INMA) —a joint institute of the CSIC and the University of Zaragoza (UNIZAR)— have developed a new method for detecting RNA viruses based on the technology of using probes that form triplex structures. This innovative methodology opens up new options to detect viruses such as SARS-CoV-2, the influenza A (H1N1) virus or the respiratory syncytial virus (RSV), a pathogen that affects newborns and requires differential diagnostic care. This[...]

15 Nov

Happy Day of Chemistry! The role of Chemistry in a sustainable research in health

Today, November 15 is a day of celebration for us, the Day of the Chemistry in Spain! Chemistry is the science that studies matter, how it is composed, its properties and how its structures are transformed and, as matter is everything, including living beings and ourselves, we can say that chemistry is omnipresent and transversal in all areas surrounding us. Chemistry is everywhere, we ourselves are chemistry and our health and our life is chemistry. “Everything around us is chemistry in the environment, foods, what we use and what we touch every day. Our own body is a sophisticated complex[...]

19 Oct

The first TECNIO Conference and NANBIOSIS’ researchers participation

More than 200 people attended the first edition of the TECNIO Conference that took place on October 19th, 2022 in Girona. Outstanding experts from research groups, companies and the Catalan administration discussed the model of technological sovereignty that Catalonia needs to generate high-impact innovation. As far as Nora Ventosa, President of the TECNIO Association and Scientific Director of NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit (from CIBER-BBN and IQAC): “Political management is the key to ensure that the path of transference follows a high speed train” Researchers of NANBIOSIS U2 Custom Antibody Service (CAbS) – Nb4D Group from CIBER-BBN and[...]

U2-Custom Antibody Service (CAbS)
Read More

U3. Synthesis of Peptides Unit

U3. Synthesis of Peptides Unit

  • Scientific Director: Dr. Miriam Royo miriam.royo@iqac.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC
IQAC CSIC

Order request

This Unit is coordinated by the Multivalent Systems for Nanomedicine goup at IQAC-CSIC and has the equipment necessary to provide services of synthesis of peptides at different scales (mg to g), purification, characterization, and post-synthesis modification, such as, conjugation to proteins and fluorescent. It counts with laboratories for synthesis and other to carry out modification of the peptides during and post synthesis labels. Also counts with a laboratory equipped with several preparative and analytical chromatography systems for purification and characterization. This facility benefits from the wide experience of Dr. Fernando Albericio an Dra. Miriam Royo in the design and synthesis of peptides with specific biological activity and the introduction of modifications necessary for these peptides to be bound to therapeutic nanoconjugates and other molecules, either to take advantage of the pharmacological activity of the peptide itself or to facilitate the introduction of nanoconjugates or other molecules into the cells in order to reach the therapeutic target. Its location allows the access to the rest of services of the IQAC-CSIC.

Active projects

Title Fundin: Organism Call: Funding source Role
ICTS-2017-10-CIBER-2 Acquisition and istallation of infrastrucuture to complemntUnis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivoExperiment Ministerio de Economía, Industria y Competitividad (MINECO) Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt) Coordinator
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant

Publications

2016

  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U3

08 Nov

Impactful research with NANBIOSIS participation in the Poster Tour of CIBER-BBN & CIBEREHD Annual Conference.

2023 CIBER-BBN Annual meeting has taken place at Santemar Hotel, in Santander during November 6-7. This year the format of our annual conferences has been changed towards a collective event scheme between the CIBER-BBN and CIBEREHD thematic areas. On Monday 6 the scientific sessions werecommon for EHD and BBN, with appealing contents for the mixed audience. On Tuesday 7 EHD and BBN sessions will specific for each area in separate rooms (with common coffee break). Posters of both areas were on display in the exhibit hall throughout the entirety of the Annual Meeting. Moreover, at the “Posters & beers” session (Monday[...]

20 Jan

New nanoarchitectonics of RGD peptide developed using quatsomes as robust tool in tissue engineering.

Researchers of three groups of CIBER-BBN at CSIC and IBEC, have created a versatile platform based on hierarchically nanostructured RGD peptide using quatsomes, with proved enhanced cell adhesion. These findings, which arose within the framework of the intramural project of CIBER-BBN “Molecular Biointerfaces for cell guidance” (DynaMo4Vasc), open new possibilities for tissue engineering. The participation of two NANBIOSIS units were acknowledged in the publication of the research results: the synthesis of RGD derivatives were performed at NANBIOSIS U3 “Synthesis of peptides unit” of CIBER-BBN at IQAC−CSIC.  And the design and characterization of quatsomes were done at U6 of NANBIOSIS “Biomateria[...]

15 Nov

Happy Day of Chemistry! The role of Chemistry in a sustainable research in health

Today, November 15 is a day of celebration for us, the Day of the Chemistry in Spain! Chemistry is the science that studies matter, how it is composed, its properties and how its structures are transformed and, as matter is everything, including living beings and ourselves, we can say that chemistry is omnipresent and transversal in all areas surrounding us. Chemistry is everywhere, we ourselves are chemistry and our health and our life is chemistry. “Everything around us is chemistry in the environment, foods, what we use and what we touch every day. Our own body is a sophisticated complex[...]

27 Jul

1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection

During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]

28 Feb

Fabry Desease in the Rare Disease Day: A New Hope

WHY DO CELEBRATE TODAY THE INTERNATIONAL #RareDiseaseDay? 29 of February is a ‘rare’ date and February, a month with a ‘rare’ number of days, has become a month to raise awareness about rare diseases and their impact on patients’ lives.  Since 2008 thousands of events happen every year all around the world and around the last day of February with the aim of improving equity and reducing stigmatization for people who live with more than 6,000 rare diseases. WHAT ARE RARE DISEASES Rare diseases are pathologies or disorders that affect a small part of the population (less than 5 per 10,000 inhabitants) and[...]

03 Feb

Multivalent self-assembled platforms for the delivery of chemotherapeutic drugs

Twenty years ago, the 4 February was declared World Cancer Day with the global challenge of cancer would not be forgotten. Since then, huge progress has been made to understand, prevent, diagnose, and treat cancer. NANBIOSIS as an ICTS (Singular Scientific and Technical infrastructures) for biomedical research plays a very important role in the fight against cancer. Dr. Miriam Royo, who leads NANBIOSIS unit 3 of Synthesis of Peptide, explains one of the projects in which the ICTS is involved in relation with cancer therapy. The improvement of solubility and stability of clinically approved chemotherapeutic drugs still represent a big[...]

26 Feb

A more effective nanomedicine has been developed for the treatment of Fabry rare disease.

28 February: International Rare Disease Day This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work.The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future.The new drug improves on current treatments and helps reduce costs and improve patients’ quality of life. Barcelona, 26 February 2021.- The advance of nanomedicine opens up new possibilities in the development of drugs, such as the one recently developed for the rare disease Fabry, with improved efficacy compared to existing[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

U3-Synthesis of Peptides Unit
Read More

U29. Oligonucleotide Synthesis Platform (OSP)

U2 CAbS-hybridoma clone
Ciber bbn

U29. Oligonucleotide Synthesis Platform (OSP)

  • Scientific Director: Prof. Ramon Eritja: recgma@cid.csic.es
  • Scientific Coordinator: Dr. Anna Aviñó: aaagma@cid.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC), Spanish National Research Council (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 145
  • Web: IQAC- CSIC
IQAC CSIC
Order request

Description

This unit is coordinated by the Nucleic Acids Chemistry Group at the Institute for Advanced Chemistry of Catalonia (IQAC), Spanish National Research Council (CSIC) and has the equipment needed for the production of oligonucleotides at low scale (mg to mg), purification, characterization and post-synthesis modification. The service counts with laboratories for synthesis and modification of oligonucleotides including DNA/RNA synthesizer, analytical and semi-preparative HPLC equipment for the purification and characterization of oligonucleotides. The service will focus in providing expert opinion to researchers as well as the production of tailored oligonucleotides. Routine synthesis of oligonucleotides used as primers will not be produced as there is a large number of commercial sources that provide a quick and low price service. The oligonucleotide synthesis platform will focus in providing modified oligonucleotides (ONs) that are difficult to obtain from commercial sources. These include microgram to milligram amounts of DNA and RNA derivatives carrying several modifications as well as oligonucleotide conjugates carrying lipids, membrane-receptors ligands, carbohydrates and peptides designed for therapeutic or diagnostic purposes. The facility benefits from the wide experience of Prof. Ramon Eritja that has more than 30 years expertise in the development of modified oligonucleotides.

Active projects

RefTitleFundin OrganismRole
CTQ2017-84415-R STUDY OF ADN STRUCTURES WITH BIOMEDICAL POTENTIALMINECOCoordinator

Other projects

RefTitleFundin OrganismRole
SBPLY/17/180501/000376Development and validation of new intelligent administration systems of RNAs in the injured spinal cord: application in a neuroprotective therapy based on miR-138Junta de Castilla-La Mancha Participant
BIO2017-92113-EXP New tailored microRNA-based antifungal agents for crop protectionMINECO - Explora-Participant
CA17103CA17103 Delivery of antisense RNA therapeutics (DARTER) C.C.E.E. COST Action Participant
AC18/00046Monitoring of Acquired Brain Injury and recovery of biomarkers by the combined label-free NanoSensing of multiple circulating molecules (ABISens).Euronanomed-III (ERA-Net cofund action on Nanomedicine)Participant
CSIC-COV19-041Point-of-care tests for the rapid detection of SARS-CoV-2 (POC4CoV) Consejo Superior de Investigaciones Científicas (CSIC)Participant
Prometeo/2020/081Use of microRNA modulators as experimental therapies in type 1 myotonic dystrophy Generalitat Valenciana Participant

Publications

2019

“Synthesis of oligonucleotides carrying nucleic acid derivatives of biomedical and structural interest” Eritja, R., Aviñó, A., Fàbrega, C., Alagia, A., Jorge, A.F., Grijalvo, S. In “Enzymatic and chemical synthesis of nucleic acid derivatives” (Fernández Lucas and Camarasa Eds) Willey-VCH Verlag, Weinheim (Germany), pp 237-258, (2019).

Cationic niosomes as non-viral vehicles for nucleic acids. Challenges and opportunities in gene delivery. Grijalvo, S., Puras, G., Zárate, J., Sainz-Ramos, M., AL Qtaish, N., López, T., Mashal, M., Attia, N., Díaz Díaz, D., Pons, R., Fernández, E., Pedraz, J.L., Eritja, R.  Pharmaceutics, 11(2), 50 (2019).

“Parallel clamps and polypurine hairpins (PPRH) for gene silencing and triplex-affinity capture: design, synthesis and use” Aviñó, A., Eritja, R., Cuidad, C., Noe, V. Current Protocols on Nucleic Acid Chemistry, e78 (2019).

“Efficient bioactive oligonucleotide-protein conjugation for cell-targeted cancer therapy” Aviñó, A., Unzueta, U., Cespedes, M.V., Casanova, I., Vázquez, E., Villaverde, A., Mangues, R., Eritja, R. ChemistryOpen, 8, 382-387 (2019).

“The small interfering RNAs (siRNAs) in cancer therapy: nano-based approach” Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C.D., Memari, F., Miri, S.R., Rad, M.R., Marmari, V. Int. J. Nanomedicine, 14, 3111-3128 (2019).

“The origins and the biological consequences of the Pur/Pyr DNA•RNA asymmetry” Terrazas, M., Genna, V., Portella, G., Villegas, N., Sánchez, D., Arnan, C., Pulido-Quetglas, C., Johnson, E., Guigó, R., Brun-Heath, I., Aviñó, A., Eritja, R., Orozco, M. Chem., 5, 1619-1631 (2019).

“On the race for more stretchable and tough hydrogels” Grijalvo, S., Eritja, R., Díaz Díaz, D. Gels, 5, 24 (2019).

“Gene delivery to the rat retina by non-viral vectors based on chloroquine-containing cationic niosomes” Mashal, M., Attia, N., Martínez-Navarrete, G., Soto-Sánchez, C., Fernández, E., Grijalvo, S., Eritja, R., Puras, G., Pedraz, J.L. J. Control. Rel., 304, 181-190 (2019).

“Study of conformational transitions of i-motif DNA using time-resolved fluorescence and multivariate analysis methods” Benabou, S., Ruckebusch, C., Sliwa, M., Aviñó, A., Eritja, R., Gargallo, R., de Juan, A.  Nucleic Acids Res., 47, 6590-6605 (2019).

“Expanding the limits of amide-triazole isosteric substitution in bisamide-based physical gels” Tautz, M., Torras, J., Grijalvo, S., Eritja, R., Saldías, C., Alemán, C., Díaz Díaz D. RSC Adv., 9, 20841-20851 (2019).

“Aptamer-peptide conjugates as a new strategy to modulate human α-thrombin binding affinity” Aviñó, A., Jorge, A.F., Huertas, C.S., Cova, T.F.G.G., Pais, A., Lechuga, L.M., Eritja, R., Fàbrega, C. Biochim. Biophys. Acta (General subjects), 1863, 1610-1630 (2019).

“Cationic niosome-based hBMP7 gene transfection of neuronal precursor NT2 cells to reduce the migration of glioma cells in vitro” Attia, N., Mashal, M., Grijalvo, S., Eritja, R., Puras, G., Pedraz, J.L. J. Drug Delivery Science Technol., 53, 101219 (2019).

“Stabilization of c-KIT G-quadruplex DNA structures by the RNA polymerase I inhibitors BMH-21 and BA-41” Mazzini, S., Gargallo, R., Musso, L., De Santis, F., Aviñó, A., Scaglioni, L., Eritja, R., Di Nicola, M., Zunino, F., Amatulli, A., Dallavalle, S. Int. J. Mol. Sci., 20, 4927 (2019).

“Alginate hydrogels as scaffolds and delivery systems to repair the damaged spinal cord” Grijalvo, S., Nieto-Díaz, M., Maza, R.M., Eritja, R., Díaz Díaz, D. Biotech J., 14, e1900275 (2019).

“A pH-dependent bolt involving cytosine bases located in the lateral loops of antiparallel G-quadruplex structures within the SMARCA4 gene promotor” Benabou S., Mazzini, S., Aviñó, A., Eritja, R. Gargallo, R. Sci. Rep., 9, 15807 (2019).

2018

Selective depletion of metastatic stem cells as therapy for human colorectal cancer. Céspedes, M.V., Unzueta, U., Aviñó, A., Gallardo, A., Álamo, P., Sala, R., Sánchez-Sardi, A., Casanova, I., Mangues, M.A., Lopez-Pousa, A., Eritja, R., Villaverde, A., Vázquez, E., Mangues, R. EMBO Mol. Med., 10, e8772 (2018).

DNA-based nanoscaffolds as vehicles for 5-fluoro-2’-deoxyuridine oligomers in colorectal cancer therapy. Jorge, A.F., Aviñó, A., Pais, A.A.C.C., Eritja, R., Fàbrega, C. Nanoscale, 10, 7238-7249 (2018).

Exploring PAZ/3’-overhang interaction to improve siRNA specificity. A combined experimental and modeling study. Alagia, A., Jorge, A.F., Aviño, A., Cova, T.F.G.G., Crehuet, R., Grijalvo, S., Alberto Pais, A.A.C.C., Eritja, R. Chem. Sci., 9, 2074-2086 (2018).

DNA origami-driven lithography for patterning on gold surfaces with sub-10 nanometer resolution. Gállego, I., Manning, B., Prades, J.D., Mir, M., Samitier, J., Eritja, R. Adv. Mat., 29, 1603233 (2017).

Glucose-nucleobase pseudo base pairs as a new biomolecular interaction in a DNA context. Vengut-Climent, E., Gómez-Pinto, I., Lucas, R., Peñalver, P., Aviñó, A., Fonseca-Guerra, C, Bickelhaupt, F.M.., Eritja, R., González, C., Morales, J.C. Angew. Chem. Int. Ed. Engl., 55, 8643-8647 (2016).

News U29

15 Feb

Women in NANBIOSIS part 1: Anna Aviñó, from Curiosity to Innovation

Anna Aviñó speaks about her journey as a researcher and her captivating oligonucleotides. This is part of a series of interviews to several female researchers within the context of International Day of Women and Girls in Science 2024. For more interviews, visit our news section here. February 2024, IQAC-CSIC/CIBER-BBN, Barcelona (Spain) Could you share with us a bit about your research area and the projects you are currently working on? I am a chemist specializing in nucleic acid chemistry. These compounds are wonderful, I would say unique; not only do they contain genetic information, but they are also involved in[...]

06 Feb

‘Magic Bullets’ Against Cancer: Unveiling the Potential of DNA Nanoparticles

DNA nanoparticles to selectively target tumor tissues through precise control of the synergies between transported drugs. February 2024, IQAC-CSIC/CIBER-BBN, Barcelona. The team led by Drs. Carme Fàbrega and Ramón Eritja, in close collaboration with 3 units of the NANBIOSIS ICTS, has developed a new strategy to improve the efficacy and reduce the toxicity of anticancer drugs. They have chemically linked several cytotoxic drugs, currently used in the treatment of various types of tumors, to DNA nanostructures. These structures selectively target cancerous tissues through folate receptors. This tactic allows precise control of drug concentration and exploits their combined effect. The results[...]

27 Feb

New method for the detection of RNA viruses such as SARS-CoV-2

Several CIBER-BBN groups at the University of Barcelona, the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC) and the Institute of Nanoscience and Materials of Aragon (INMA) —a joint institute of the CSIC and the University of Zaragoza (UNIZAR)— have developed a new method for detecting RNA viruses based on the technology of using probes that form triplex structures. This innovative methodology opens up new options to detect viruses such as SARS-CoV-2, the influenza A (H1N1) virus or the respiratory syncytial virus (RSV), a pathogen that affects newborns and requires differential diagnostic care. This[...]

15 Nov

Happy Day of Chemistry! The role of Chemistry in a sustainable research in health

Today, November 15 is a day of celebration for us, the Day of the Chemistry in Spain! Chemistry is the science that studies matter, how it is composed, its properties and how its structures are transformed and, as matter is everything, including living beings and ourselves, we can say that chemistry is omnipresent and transversal in all areas surrounding us. Chemistry is everywhere, we ourselves are chemistry and our health and our life is chemistry. “Everything around us is chemistry in the environment, foods, what we use and what we touch every day. Our own body is a sophisticated complex[...]

27 Jul

1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection

During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]

03 May

OPEN SUBMISSION FOR JOURNAL SPECIAL ISSUE ON OLIGONUCLEOTIDE BASED THERAPIES

Dr. Ramon Eritja, Scientific Director of NANBIOSIS unit 29 of Oligonucleotide Synthesis Platform (OSP) and Dr. Santiago Grijalvo researcher at NANBIOSIS unit 12 of Nanostructured liquid characterization, from CIBER-BBN and IQAC-CSIC, together with Dr. Andreia F. Jorge, from Coimbra Chemistry Centre (CQC), acting as guest editors of journal Pharmaceutics, of MDPI Publisher, welcome authors to submit their articles on special issues on Recent Trends in Oligonucleotide Based Therapies. In the past few decades, significant efforts have been made towards the clinical application of oligonucleotides. However, the potential of the therapeutic applications of RNA-based strategies have recently been spotlighted after the first approval of mRNA vaccines in response to COVID-19[...]

02 May

Wide representation of NANBIOSIS research in NALS 2022 and best Oral Presentation to Eloi Parladé

During the last 27-29 April, the 3rd International Conference on Nanomaterials Applied to Life Sciences 2022 (NALS 2022) has taken place in the Excellence Campus of Universidad de Cantabria in Santander (Spain), organized by the University of Cantabria and Institute Valdecilla-IDIVAL. NALS 2022 has been a multidisciplinary conference series sharing new results and ideas in the fields of biosensors, lab on a chip, drug delivery nanopharmacy. nanobiotechnology, intelligent nanomaterials, magnetic materials, nanotoxicity, antimicrobials, novel applications of 3d bioprinting and nanoimaging. NANBIOSIS has been represented at this edition by members of several of its units, among them we must highlight the set of four ora[...]

27 Apr

OPEN SUBMISSION FOR FRONTIERS IN CHEMISTRY SPECIAL ISSUE ON NUCLEIC ACID-BASED APTAMERS IN THERAPEUTICS AND DIAGNOSTICS

Dr. Anna Aviñó, Scientific Coordianator of NANBIOSIS unit 29 of Oligonucleotide Synthesis Platform (OSP) and Dr. Carme Fàbrega from the Nucleic Acid Chemistry group from CIBER-BBN and IQAC_CSIC, together with Dr. Claudia Riccardi from the University of Naples Federico II, Dr. Stefania Mazzini from University of Milan, and Dr. Raimundo Gargallo from the University of Barcelona, acting as guest editors of the journal Frontiers in Chemistry, welcome authors to submit their articles on special issues on Nucleic Acid-Based Aptamers in Therapeutics and Diagnostics. Nucleic acid‐based aptamers are short DNA or RNA sequences able to adopt specific three‐dimensional architectures. The high affinity and selectivity shown for a selected target, as well as t[...]

U29. Oligonucleotide Synthesis Platform
Read More